CytomX Therapeutics Inc. (CTMX)
The price, the headline numbers and the latest news, in one place.
CytomX Therapeutics Inc. (CTMX) Stock Price, Analysis & Data
| Bid | 2.44 |
| Market Cap | 714.71M |
| Revenue (ttm) | 18.3M |
| Net Income (ttm) | -82.66M |
| 2.14 | |
| -0.57 | |
| n/a | |
| -6.93 | |
| P/B (ttm) | 2.37 |
| P/S (ttm) | 39.05 |
| Earnings Date | Aug 7, 2025 |
| Ask | 4.24 |
| Volume | 2,894,708 |
| Avg. Volume (20D) | 3,985,764 |
| Open | 3.31 |
| Previous Close | 3.29 |
| Day's Range | 3.27 - 3.42 |
| 52-Week Range | 1.90 - 8.21 |
| Analyst | Strong Buy |
| Price Target | 12 (265.85%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increa...
Financial Performance
In 2025, CytomX Therapeutics's revenue was 76.2M, a decrease of -44.82% compared to the previous year's 138.1M. Earnings were -17.37M, a decrease of -154.5%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for CTMX stock is "Strong Buy". The 12-month stock price forecast is 12, which is upside of 265.85% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.42M misses estimates by $0, with -92.40% YoY decline.
- EPS of -0.09 exceeds estimates by 0.01, with -133.33% YoY decline.
Analysts project revenue of ... Upgrade
